Longboard Pharmaceuticals ( NASDAQ:LBPH – Get Rating ) had its price objective cut by Citigroup from $24.00 to $17.00 in a report released on Sunday morning, The Fly reports. They currently have a buy rating on the stock. A number of other equities research analysts also recently commented on the company. Guggenheim cut their price objective on Longboard Pharmaceuticals from $18.00 to $16.00 and set a buy rating for the company in a research report on Friday, November 11th. Wedbush reissued an outperform rating on shares of Longboard Pharmaceuticals in a research note on Friday, March 3rd.

https://www.dailypolitical.com/2023/03/08/longboard-pharmaceuticals-nasdaqlbph-price-target-cut-to-17-00-by-analysts-at-citigroup.html

#dailypolitical